Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06142383 · ClinicalTrials.gov registry record · Phase 2
A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure
A Phase 2 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 2
- Development phase
- 136
- Enrollment target
NCT06142383 is a Phase 2 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 136 participants.
The verdict
NCT06142383, a Phase 2 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 2
- Development phase
- 136 participants
- Enrollment target
Study Summary
This was a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
Interventions
- BIOLOGICAL Placebo
- DRUG Sacubitril/valsartan
- BIOLOGICAL XXB750 Low dose
- BIOLOGICAL XXB750 Medium Dose
- BIOLOGICAL XXB750 High Dose
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 136 participants |
| Start Date | 2023-12-12 |
| Est. Completion | 2024-11-01 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06142383
The ClinicalTrials.gov registry entry for NCT06142383 describes a study currently listed as terminated, categorized as Phase 2. The registered enrollment target is 136 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 5 interventions - of which Placebo is the first listed.
NCT06142383 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06142383 about?
NCT06142383 is a clinical study titled "A Proof of Concept and Dose-finding Study of XXB750 in Patients With Heart Failure". This was a multicenter, randomized, placebo- and active-controlled, parallel-group, 24-week trial to investigate the efficacy, safety, and tolerability of XXB750 in participants with HFrEF/HFmrEF.
What is the current status of trial NCT06142383?
This trial is currently terminated. It is a Phase 2 study. The enrollment target is 136 participants. The study started on 2023-12-12. Estimated completion is 2024-11-01.
What interventions are being tested in trial NCT06142383?
The interventions under investigation include: Placebo (BIOLOGICAL), Sacubitril/valsartan (DRUG), XXB750 Low dose (BIOLOGICAL), XXB750 Medium Dose (BIOLOGICAL), XXB750 High Dose (BIOLOGICAL).
Who is sponsoring clinical trial NCT06142383?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.